Published in Gene Therapy Weekly, February 24th, 2000
"Recombinant, replication competent RV vaccine strain-based vectors expressing HIV-1 envelope protein (gp160) were constructed from both a laboratory adapted (CXCR4-tropic) and a primary (dual-tropic) HIV-1 isolate," said M.J. Schnell and colleagues from the Dorance H. Hamilton Laboratories, USA.
Schnell et al. presented data from their work at the 7th Conference on Retroviruses and Opportunistic Infections, held January 30 - February 2, 2000, in San Francisco, California, USA. The title of their presentation was "Recombinant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.